Paper 2581

ISSN (Online) 2581-9429
IJARSCT
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 2, Issue 1, February 2022

Impact Factor: 6.252
Computer Aided Drug Design

Ms. Shubhangi Manikpuriya1, Mr. Shubham Girnare2, Mr. Akash Shinde3, Dr. Gajanan Sanap4
Assistant Professor, Late Bhagirathi Yashwantrao Pathrikar College of D. Pharmacy, Pathri, Phulambri, Aurangabad1
Students, Late Bhagirathi Yashwantrao Pathrikar College of D. Pharmacy, Pathri, Phulambri, Aurangabad2,3
Principal, Late Bhagirathi Yashwantrao Pathrikar College of D. Pharmacy, Pathri, Phulambri, Aurangabad4
Abstract: Computational approaches in drug style, discovery and admiration. Generally, drug discovery
takes an extended Duration of your time amount Ni twelve year and billon of capital. It includes the making
of recent molecules, docking Molecules to focus on macromolecule, analyzing molecular interaction,
estimating binding strength and drug properties. Computer power-assisted Drug planning (CADD) is value
effective and freed from some biological trials. It mainly consists of 2 styles of drug style that’s structure -
based drug style and ligand-based drug style. Through it we are able to comprehend the drug receptor
interaction. Structure primarily based Drug style includes binding Site identification, arrival and stocking,
virtual screening, compound choice, lead optimization. Ligand Based Drug style includes quantitative
structure activity relationship, medicine modelling and steps Followed as structure- primarily based drug
style. As we are able to see CADD facilitate to acknowledge appropriate characteristics of a Drug and its
compatibility to induce a straightforward hand in pre- clinical trials.
Keywords: Ligand Base Drug Style, Structure Base Drug Style, CADD, Target Protein and Binding
I. INTRODUCTION
Computational approaches in drug style, discovery and development method gaining terribly fast exploration,
implementation and administration. Introducing a replacement drug in a market could be a terribly advanced, risky and
dear method in terms of your time, cash and workforce. Typically it’s found that drug discovery and development method
takes around one0-14 years and quite 1 billion bucks capital in total (1). So for reducing time, price and risk borne factors
computer power-assisted drug style (CADD) methodology is wide used as a brand new drug style approach. It’s been
seen that by the employment of CADD approaches we will reduced the cost of drug discovery and development up to
five hundredth a pair (2). CADD consist use of any software package program based mostly process for establishing a
typical to relate activity to structure (3). The Computer power-assisted Drug style (CADD) represents the role within the
fashionable strategy of the medical specialty arena hat is rising thanks to discovery and style of the new effective
therapeutic agents with the assistance of Computer within the drug style method. A drug target may be a key molecule
concerned specifically metabolic Pathway that is related to a particular malady, pathology, survival of microbic
microorganism. A drug have a specific to focus on and it’s terribly Brobding nagia method or advanced method. This
method started once a chemist identifies The drug candidate, that shows the biological profile and completed the each
optimized chemical synthesis and activity profile of the novel chemical entity(4). (5) Discovery and development of made
drug is generally called terribly advanced method, that takes concerning billion bucks and it additionally needed minimum
twelve Years for fulfil high value, deficient long amount of your time the danger of the failure is exaggerated to just about
ninetieth and Almost 70%funds area unit costed on failure thanks to lack of potency or adverse aspect effects through
clinical Trails So to return these issues CADD is employed. (6,7 )three- dimensional organization of the receptor is
employed to delever evalope a ‘novel’ molecule for the de novo drug style. This is often continuous method which makes
the involvement of determination of structure with the lead target and modification of the lead. (8)The complicated
method drug style is extremely essential to create pharmaceutical drug developments with the in today’s the quick growth
within the field of pharmaceutical medication and these medication was discovered to use or form of malady.
Copyright to IJARSCT DOI: 10.48175/IJARSCT-2581 563

www.ijarsct.co.in
IJARSCT

Figure 1: General Principle for Drug design through CADD.
NOTE:
In today’s the quick growth within the field of pharmaceutical medication and these medication was discovered to use
or style of unwellness. For the reduction within the time and value the process approaches emerged in 1960’s by Hansch
and fujita,used to mechanistic pathways of the unwellness, and analyse the drug. Computeraided drug style (CADD) is
incredibly great tool in rational drug style. it's used to facilitate the target identification ,validation ,optimization of the
ADMET (absorption, distribution, metabolism, excretion and toxicity) profile of safe drug .The large quantity of the
chosen molecules area unit synthesised compound area unit tested through biological assay and screens, takes heap of
your time and capital , however CADD has ability to scale back time duration and value and additionally verify the
amount and biological activity of big amount of compounds with the help of CADD is feasible to elucidate the molecular
therapeutic activity. There area unit such a big amount of antibiotic drugs area unit employed in daily routine by the
Human to kill the microorganism, that is answerable for microorganism infection. Some microorganism life resist to
those antibiotics area unit referred to as antibiotics drug resistance. Therefore it's required to style and invent new
antibiotics. The identification of latest antibiotic target is answer of the antibiotics resistance that represent novel
mechanism essential for microorganism survival.
II. MAJOR TYPE IN CADD

There are mainly two types of approaches for drug design through CADD is the following:
1. Structure based drug design / direct approach
2. Ligand based drug design / indirect approach
2.1 Structure Based Drug Design

In SBDD, structure of the target super molecule is thought and interaction or bio-affinity for all tested compounds
calculate when the method of docking; to style a brand new drug molecule, that shows higher interaction with target
super molecule (9).Structure based mostly drug style (SBDD) is that the method which incorporates virtual screening
and diamond state novo drug style course. In virtual screening the drug compound square measure procedure screened
against the celebrated target Structure (10,11).

www.ijarsct.co.in
IJARSCT

Figure 2: General Representation of workflow for CADD.
Figure 3: Layout of SBDD (12)
A. Overview of the process involved in SBDD

SBDD runs through many cycles before the optimized lead reached into clinical trials. the primary cycle includes
isolation, purification and structure determination of the target super molecule by one all told three key methods: like X-
ray physics, similarity modeling or resonance. Exploitation compounds comes through virtual screening of various
databases ar placed into a selected region (active site) of the super molecule. These compounds are scored and hierarchic
www.ijarsct.co.in
IJARSCT

on the bases of steric, hydrophobic, static interaction of those molecules with the situation of target super molecule. Top
ranked compounds are tested with organic chemistry assays. Second cycle contains structure determination of the protein
in advanced with the foremost optimistic lead of the first cycle, the one with minimum micro-molar inhibition in-vitro,
and shows sites of the compound which can be optimized for additional increment within the potency. when many extra
cycles like synthesis of lead, additional improvement of lead through advanced structure of super molecule with lead
compound, the optimized compounds typically show marked increment within the target specificity and binding
affinity(13) .
B. Target Protein and Binding

The target macromolecule identification is that the basic step within the SBDD method (14). The binding web site of
target Macromolecular provided the clear info regarding protein-ligand interaction, post-docking dynamics and Also
bond formation, that helps to calculate the most effective pharmacophores of the ‘novel’ matter (15).Binding sites
determined through an experiment by integrative structure biology techniques within the 3D structure Of target organic
compound such as proton magnetic resonance, X-ray natural philosophy.(16). Future step is to spot the binding Pocket
once the target macromolecule is resolved. It’s terribly tiny cavity wherever the matter binds and conjointly shown their
Therapeutic or desired impact. These ways offer the information regarding the energy interaction and Van derwaals
(vdW) forces for binding web site mapping. There area unit several ways area unit developed by the energy Interaction
calculations specifically for SBDD for binding web site mapping and these ways identifies the Particular sites of target
macromolecule, that act with favourable useful teams on medication. These are Identifying with the macromolecule Q-
site Finder (17).
2.2. Ligand-Based Drug Design

In LBDD, 3D structure of the target macromolecule isn't well-known however the data of ligands that binds to the
specified Target website is thought. These ligands may be accustomed develop a pharmacophore model or molecule that
possesses all necessary structural options for bind to a target site.
Figure 4: Outline of process involved in LBDD (18)
A. QSAR
The QSAR technique a vital a part of drug improvement method. To quantify the correlation between the chemical
structure and process of a series of compounds the QSAR technique is employed (19,20). The developed QSAR Model
is used as guiding tool for identification of compound to modification and also optimize the active compound to Maximize
relevant biological activity.
www.ijarsct.co.in
IJARSCT

The methods some are used in QSAR

1. Measure value of desired biological activity and then, identify the ideal ligand
2. Determine molecular descriptors with physic-chemical properties of molecules.
3. The molecular description and biological activity correlation discover.
4. The last test QSAR model for statistical stability.
B. Molecular Docking
Molecular arrival is in-silico technique that predicts the placement of tiny molecules or ligands at intervals the active
site of their target macromolecule (receptor). It’s primarily used to correct estimation of most favorable binding modes
and bio-affinities of ligands with their receptor, presently it’s been broadly speaking applied to virtual screening for the
optimisation of the lead compounds.
Figure 5: Process of Docking (22)

Molecular moorage could be a technique of virtual Simulation that is employed to model the interaction between alittle
Molecule and a macromolecule at the atomic level. This system is additionally wont To characterize the behaviour of the
Small molecules within the binding web Site of target macromolecule (22,23).
Figure 6: Overview of Virtual screening process (25)
C. Virtual Screening
Virtual screening could be a process methodology utilized in drug style. During this methodology the big libraries of
compounds are Bind with specific web site on the target molecules such as- proteins and well-compounds tested. Virtual
www.ijarsct.co.in
IJARSCT

screening is additionally Helping to seek out or establish those structures that are presumably to bind to a drug target
(protein receptors or Enzyme).Virtual screening has become associate integral half of drug target (typically, super
molecule receptor or enzyme) and drug discovery process. Though filtering chemical universe is also additional sensible
virtual screening scenarious specialise in optimizing targeted combinative libraries of asseccible compounds from in-
house compound repositories. Virtual screening is a smaller amount Expensive, less time intense, scanning the larger
variety of potential medication and also very quicker than standard screening (24).
Advantages of CADD
1. Through it we will cut back the artificial and biological testing efforts (26).
2. It offers the foremost promising drug candidate by eliminate the compounds with undesirable properties (poor
effectuality, poor ADMET etc.) through in silico filters it’s an economical, time saving, Rapid and automatic
method (27).
3. Through it we will comprehend the drug-receptor interaction pattern.
4. It offers compounds with high hit rates through searching vast libraries of compounds in-silico in comparison
to ancient high output screening.
5. These approaches minimize probabilities of failures in the final part(28).
D. Homology Modeling
Another common challenge in CADD analysis is determining the 3D structure of proteins. Most drug targets square
measure proteins, thus it’s vital to grasp their 3D structure very well. It’s calculable that the body has 500,000 to one
million proteins. However, the 3-D structure is understood for under alittle fraction of those. Homology modeling is one
technique accustomed predict 3D structure. In similarity modeling, the organic compound sequence of a selected
macromolecule (target) is understood, and the 3-D structures of proteins associated with the target (templates) square
measure illustrious. Bioinformatics software package tools square measure then accustomed predict the 3D structure of
the target based mostly on the illustrious 3D structures of the templates [37].
MODELLER may be a well-known tool in similarity modeling, and the SWISS-MODEL Repository may be a info of
macromolecule structures created with similarity modeling.
E. Pharmacophore
The schematic representation of bioactive functional group’s along with their interatomic distance is known as
‘pharmacophore
a. History of Pharmacophore
The original idea of the pharmacophore was developed by ‘Paul Ehrlich’ throughout late 1800s [38]. At that time, the
understanding was that sure chemical teams or functions in a very molecule were accountable for a biological impact,
and molecules with similar effects had similar functions in common. The word ‘pharmacophore’ was coined abundant
later, by ‘Suhveler’ in his book Chemo-biodynamics and drug design, and was outlined as a molecular framwork that
carries (phoros) the essential options accountable for a drug’s pharmacon biological activity. [39] The pharmacophore
idea is extremely massive role in pc assisted drug design (CADD). The options area unit pharmacophore reduced by
some atoms and molecules that exhibits properties. These molecules area unit referred to as chemical bond donors or
acceptors, cation, anionic, aromatic, or hydrophobic and any potential combination. [40]

www.ijarsct.co.in
IJARSCT

Figure 7: Pharmacophore
b. Pharmacophore Fingerprint and Model

The pharmacophore reduces assortment of options of molecules at the 2nd or 3D level. [41, 42]. A pharmacophore
fingerprint represents little molecule matter. Pharmacophore fingerprint may be accustomed analyse the similarity
between molecules or among a library of molecules. Pharmacophore model is additionally referred to as ‘query’. The
few options ar organized during a specific 3D pattern in pharmacophore model [43]. the tiny molecules libraries ar
employed in the pharmacophore options on screen[44]
F. Limitations
Despite variety of booming applications of CADD to trendy drug style, it's its limitations. above all, like every laptop
assisted theoretic system results should be valid in actual systems, and lots of lead molecules known victimisation CADD
have did not exhibit desired activities in biological systems [29, 30]. many parameters should be met before potential
compound to be approved as potent lead/drug, because it needs to pass many medical specialty criteria. In fact, a mean
of solely four-hundredth of lead/drug candidates passes the various phases of clinical trials and obtains approval for
clinical use. Any machine tool supported pre-defined algorithms and scripts has its limitations, and also the machine
tools/methods utilized in CADD, such as, molecular moorage, virtual screening, QSAR, pharmacophore modeling, and
molecular dynamics, have their own limitations [49, 31-34]. what is more, ADME and lots of toxicity prediction tools
aren't supported by solid experimental knowledge, and lots of samples of the failure of those machine approaches is found
within the literature [35, 36]. To overcome limitations and improve accuracy in terms of predicting potent leads, regular
updates of tools and algorithms area unit required. information responsibility and top quality valid experimental
molecules is to be developed and updated as a result of several pharmacophores don't pass biological activity method
because of non-availability of excellent quality knowledge sets. Databases ought to contain detail knowledge on genetics
and genetic science, top quality sequence data, chemistry properties, and structures.
III. CONCLUSION
In the use of drug design and development these are several reasons to use the modern techniques of CADD. The
backbone of modern CADD process is the structure-based ligand-based drugs design methods along with molecular
dynamics simulation. Various success stories of CADD and their limitations are discussed in the same project. To
improve research quality and to facilitate identification of new chemical entities leading to development of useful drugs,
it is necessary to use the clear concept and advanced knowledge of CADD method.
ACKNOWLEDGMENT
The authors would like to express sincere gratitude to the management of late Bhagirathi Yashwantrao Pathrikar
College of pharmacy for their continuous support and encouragement in this work.

www.ijarsct.co.in
IJARSCT

REFERENCES
[1]. Daina A, Blatter MC, Baillie Gerritsen V, Palagi PM, Marek D, Xenarios I, et al. Drug Design Workshop: A
Web-Based Educational Tool To Introduce Computer-Aided Drug Design to the General Public. Journal of
Chemical Education. 2017; 94(3):335- 44.
[2]. Xiang M, Cao Y, Fan W, Chen L, Mo Y. Computer-aided drug Design: lead discovery and optimization.
Combinatorial Chemistry & high throughput screening. 2012; 15(4):328-37.
[3]. Hopfinger AJ. Computer-assisted drug design. Journal of Medicinal chemistry. 1985; 28(9):1133-9
[4]. Kapetanovic I.M. Computer-aided drug discovery and development (CADDD): in silico-chemico-Biological
approach. Chem. Biol. Interact. 2008;171(2):165–176. [http://dx.doi.org/ 10.1016/j.cbi.2006.12.006]. [PMID:
17229415]. [PMC free article] [PubMed] [Google Scholar]
[5]. Song C.M., Lim S.J., Tong J.C. Recent advances in computer-aided drug design. Brief. Bioinform.
2009;10(5):579–591. [http://dx.doi.org/10.1093/bib/bbp023]. [PMID: 19433475]. [PubMed] [Google Scholar]
[6]. Sliwoski G., Kothiwale S., Meiler J., Lowe E.W., Jr Computational methods in drug Discovery. Pharmacol.
Rev. 2013;66(1):334–395 [http://dx.doi.org/10.1124/pr.112.007336]. [PMID: 24381236]. [PMC free article]
[PubMed] [Google Scholar
[7]. 7.Selvaraj C., Omer A., Singh P., Singh S.K. Molecular insights of protein contour recognition with Ligand
pharmacophoric sites through combinatorial library design and MD simulation in validating HTLV-1 PR
inhibitors. Mol. Biosyst. 2015;11(1):178–189. [http://dx.doi.org/10.1039/C4MB00486H]. [PMID: 25335799].
[PubMed] [Google Scholar]
[8]. Tripathi S.K., Singh S.K. Insights into the structural basis of 3,5-diaminoindazoles as CDK2 Inhibitors:
prediction of binding modes and potency by QM-MM interaction, MESP and MD Simulation. Mol. Biosyst.
2014;10(8):2189–2201. [http://dx.doi.org/10.1039/ C4MB00077C]. [PMID: 24909777]. [PubMed] [Google
Scholar]
[9]. Imam SS, Gilani SJ. Computer Aided Drug Design: A Novel Loom To Drug Discovery. Org. Med. Chem. 2017;
1(4):1-6.
[10]. .Lavecchia A, Di Giovanni C. virtual screening strategies in drug discovery a critical review. Curr. Med. Chem.
2013;20(23); 2839-2860. Doi:10. 2174/09298673113209990001.
[11]. Reddy A.S, Pati S.P, Kumar P.P, Pradeep H.N, Sastry G.N. virtual screening in drug discovery- a
Computational perspective Curr. Protein pept. Sci. 2007;8(4):329-351:doi:10.2174/13892030778136947.
[12]. Ferreira LG, dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design
strategies. Molecules. 2015; 20(7):13384-421
[13]. Anderson AC. The process of structure-based drug design.Chemistry & biology. 2003; 10(9):787-97.
[14]. Grant M.A. Protein structure prediction in structure-based ligand design and virtual screening. Comb. Chem.
High Throughput Screen. 2009;12:940–960. Doi: 10.2174/138620709789824718. [PubMed] [CrossRef]
[Google Scholar]
[15]. Zhang Y.; hand.; Tian H.; Jiao Y.; Shi Z.; Ran T.; Liu H.; Lu S.; Xu A.; Qiao X.; Pau J.; Yin L.; Zhou W.; Lu
T.; Chen Y.; identification of covalent binding sites targeting cryteines based on computational approaches Mol.
Pharma,2016,13(9) 3106-3118.
[16]. 16. Pau L.; Gardner, C.L.; Pugliai, F.A.; honzalez, teleonomic acid binding pocket in prb from liberibacter
Asiaticus. Front microbiol.,2017,8,1591
[17]. Laurie A.T., Jackson R.M. Q-sitefinder: An energy-based method for the prediction of protein-ligand Binding
sites. Bioinformatics. 2005;21:1908–1916. Doi: 10.1093/bioinformatics/bti315. [PubMed] [CrossRef] [Google
Scholar]
[18]. Hoque I, Chatterjee A, Bhattacharya S, Biswas R. An Approach of Computer-Aided Drug Design (CADD)
Tools for In Silico Pharmaceutical Drug Design and Development. Int. J. Adv. Res. Biol. Sci. 2017; 4(2) 60-71
[19]. Akamatsu M. Current State and Perspectives of 3D-QSAR. Curr. Top. Med. Chem. 2002;2:1381–1394.
[PubMed] [Google Scholar]

www.ijarsct.co.in
IJARSCT

[20]. Verma RP, Hansch C. Camptothecins: A SAR/QSAR Study. Chem. Rev. 2009;109:213–235. [PubMed]
[Google Scholar]
[21]. Hernández-Santoyo A, Tenorio-Barajas AY, Altuzar V, Vivanco-Cid H, Mendoza-Barrera C. Protein-protein
and Protein-ligand docking. InProtein engineering-technology and Application 2013. InTech.
[22]. Prada-Gracia D., Huerta-Yepez S., Moreno-Vargas L.M. Application of computational methods for Anticancer
drug discovery, design, and optimization. Bol. Med. Hosp. Infan.t Mex. 2016;73:411–423. [PubMed] [Google
Scholar]
[23]. 23. Clark D.E. What has computer-aided molecular design ever done for drug discovery? Expert Opin. Drug
Discov. 2006;1:103–110. Doi: 10.1517/17460441.1.2.103. [PubMed] [CrossRef] [Google Scholar]
[24]. Reddy AS, Pati SP, Kumar PP, Pradeep HN, Sastry GN; Virtual screening in drug discovery-A computational
Perspective; Current protein and peptide science; 2007; 8; 329-351.
[25]. Maithri G, Manasa B, Vani SS, Narendra A, Harshita T. Computational drug design and molecular dynamic
studies—a Review. Biomedical Data Mining. 2016; 5:1-7.
[26]. Zhang S. Computer-aided drug discovery and development. In Drug Design and Discovery. 2011; 716:23-38.
[27]. Kapetanovic IM. Computer-aided drug discovery and Development (CADD): insilico-chemico-biological
approach. Chemico-biological interactions. 2008; 171(2):165-76
[28]. Shekhar C. In silico pharmacology: computer-aided methods Could transform drug development. Chemistry
& biology. 2008; 15(5):413-4.
[29]. Schneider G. Virtual screening: an endless staircase? Nat. Rev. Drug Discov. 2010;9(4):273–
276. [http://dx.doi.org/10.1038/ nrd3139]. [PMID: 20357802].
[30]. Verkhivker G.M., Bouzida D., Gehlhaar D.K., Rejto P.A., Arthurs S., Colson A.B., Freer S.T., Larson V., Luty
B.A., Marrone T., Rose P.W. Deciphering common failures in molecular docking of ligand-protein
complexes. J. Comput. Aided Mol. Des. 2000;14(8):731–751. [http://dx.doi.org/10.1023/A:1008158231558].
[PMID: 11131967].
[31]. Cheatham T.E., III, Young M.A. Molecular dynamics simulation of nucleic acids: successes, limitations, and
promise. Biopolymers. 2000-2001;56(4):232–256. [http://dx.doi.org/10.1002/1097-0282 (2000)56:4<232:AID-
BIP10037>3.0.CO;2-H]. [PMID: 11754338].
[32]. Klebe G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov. Today. 2006;11(13-
14):580–594. [http://dx.doi.org/10.1016/j.drudis.2006.05.012]. [PMID: 16793526].
[33]. Korb O., Olsson T.S., Bowden S.J., Hall R.J., Verdonk M.L., Liebeschuetz J.W., Cole J.C. Potential and
limitations of ensemble docking. J. Chem. Inf. Model. 2012;52(5):1262–1274. [http://dx.doi.org/10.102
1/ci2005934]. [PMID: 22482774]
[34]. MacDonald D., Breton R., Sutcliffe R., Walker J. Uses and limitations of quantitative structure-activity
relationships (QSARs) to categorize substances on the Canadian domestic substance list as persistent and/or
bioaccumulative, and inherently toxic to non-human organisms. SAR QSAR Environ. Res. 2002;13(1):43–
55. [http://dx.doi.org/10.1080/10629360290002082]. [PMID: 12074391].
[35]. Blomme E.A., Will Y. Toxicology Strategies for Drug Discovery: Present and Future. Chem. Res.
Toxicol. 2016;29(4):473–504. [http:// dx.doi.org/10.1021/acs.chemrestox.5b00407]. [PMID: 26588328].
[36]. van de Waterbeemd H., Gifford E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug
Discov. 2003;2(3):192–204. [PMID: 12612645].
[37]. Park D S, Kim J M, Lee Y B, Ahn C H. QSID Tool: a new three-dimensional QSAR environmental tool.
Journal of Computer-Aided Drug Design. 2008; 22 (12): 873-883.
[38]. Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug
38. molecules to correlate and predict their biological activity. J. Med. Chem. 1994;37:4130– 4146
[39]. Turner DB, Willett P. The EVA spectral descriptor. Eur. J. Med. Chem. 2000;35:367–375.
[40]. Whitley DC, Ford MG, Livingstone DJ. Unsupervised forward selection: a method for eliminating redundant
variables. J. Chem. Inf. Comput. Sci. 2000;40:1160–1168.

www.ijarsct.co.in
IJARSCT

[41]. Chen H, Zhou J, Xie G. PARM: a genetic evolved algorithm to predict bioactivity. J. Chem. Inf. Comput. Sci.
1998;38:243–250.
[42]. Rogers D, Hopfinger AJ. Application of genetic function approximation to quantitative structure activity
relationships and quantitative structure-property relationships. J. Chem. Inf. Comput. Sci. 1994;34:854–866
[43]. Itskowitz P, Tropsha A. k nearest neighbors QSAR modeling as a variational problem: theory and applications.
J. Chem. Inf. Model. 2005;45:777–785.
[44]. Jain AN, Koile K, Chapman D. Compass: Predicting biological activities from molecular surface properties.
performance comparisons on a steroid benchmark. J. Med. Chem. 1994;37:2315–2327.

www.ijarsct.co.in

Paper 2581

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Paper 2581

Uploaded by

Copyright:

Available Formats

ISSN (Online) 2581-9429

Volume 2, Issue 1, February 2022

Computer Aided Drug Design

Copyright to IJARSCT DOI: 10.48175/IJARSCT-2581 563

Volume 2, Issue 1, February 2022

Figure 1: General Principle for Drug design through CADD.

II. MAJOR TYPE IN CADD

2.1 Structure Based Drug Design

Copyright to IJARSCT DOI: 10.48175/IJARSCT-2581 564

Volume 2, Issue 1, February 2022

Figure 2: General Representation of workflow for CADD.

Figure 3: Layout of SBDD (12)

A. Overview of the process involved in SBDD

Volume 2, Issue 1, February 2022

B. Target Protein and Binding

2.2. Ligand-Based Drug Design

Figure 4: Outline of process involved in LBDD (18)

Volume 2, Issue 1, February 2022

The methods some are used in QSAR

Figure 5: Process of Docking (22)

Figure 6: Overview of Virtual screening process (25)

Volume 2, Issue 1, February 2022

Copyright to IJARSCT DOI: 10.48175/IJARSCT-2581 568

Volume 2, Issue 1, February 2022

b. Pharmacophore Fingerprint and Model

Copyright to IJARSCT DOI: 10.48175/IJARSCT-2581 569

Volume 2, Issue 1, February 2022

Copyright to IJARSCT DOI: 10.48175/IJARSCT-2581 570

Volume 2, Issue 1, February 2022

Copyright to IJARSCT DOI: 10.48175/IJARSCT-2581 571

Volume 2, Issue 1, February 2022

Copyright to IJARSCT DOI: 10.48175/IJARSCT-2581 572

You might also like